Broadcom named strategic vendor for Walmart virtualization solutions
Ceribell, Inc., a $642 million market cap company specializing in electromedical and electrotherapeutic apparatus, held its 2025 Annual Meeting of Stockholders on June 10, 2025. The company, which boasts impressive gross profit margins of 87% according to InvestingPro data, gathered shareholders to vote upon two key proposals.
The first proposal involved the election of Class I directors. Juliet Tammenoms Bakker and Lucian Iancovici, M.D. were elected to serve as directors until the 2028 Annual Meeting of Stockholders. The votes were cast as follows: Bakker received 20,199,817 votes for, 2,031,435 withheld, and 1,090,816 broker non-votes. Iancovici garnered 19,009,795 votes for, 3,221,457 withheld, and again 1,090,816 broker non-votes.
The second proposal was to ratify the appointment of PricewaterhouseCoopers LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. This proposal was approved with 23,287,906 votes for, 1,440 against, and 32,722 abstained.
The results of the stockholder’s votes indicate continued support for the current direction of the company’s leadership and its choice of auditor. This information is based on a press release statement provided by Ceribell, Inc.
In other recent news, CeriBell Inc. reported a significant 42% increase in revenue for the first quarter of 2025, totaling $20.5 million. Despite a net loss of $12.8 million, the company has raised its full-year revenue guidance to between $83 million and $87 million, reflecting management’s confidence in continued growth. CeriBell’s gross margins remain strong at 88%, even as the company faces potential tariff challenges on China-sourced goods. The company also received FDA clearance for a new pediatric seizure detection algorithm, expanding its market reach. Analyst firm TD Cowen maintained a Buy rating on CeriBell, with a price target of $36, citing potential benefits from easing US-China trade tensions. The firm believes that a trade deal could improve CeriBell’s cost structure and enhance profitability. Investors are closely monitoring these developments, as they could significantly impact CeriBell’s financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.